Barclays’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Barclays’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-35,000	Closed	-$1.53M	–	7542
2019 Q2	$1.53M	Buy	+35,000	New	+$1.97M	﹤0.01%	3215
2018 Q2	–	Sell	-71,700	Closed	-$1.85M	–	7685
2018 Q1	$1.85M	Buy	+71,700	New	+$2.14M	﹤0.01%	2537

Other funds holding BHVN

LIP

Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Barclays's BHVN Position: Q4 2022 in Review

Barclays sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 218,095 shares — an estimated $33M sold.

Barclays first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $33M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

Barclays reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
Barclays sold 218,095 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $33M.
Barclays first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
Barclays's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33M in Q3 2022.
7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.